Novo Nordisk · 20 hours ago
Internship - Obesity Commercial Insights
Plainsboro, NJ, US
Internship
Onsite
InternNovo Nordisk is a global pharmaceutical company focused on creating lasting change for long-term health. The internship program offers students the chance to gain hands-on experience by collaborating with professionals, integrating consumer insights, and enhancing deliverables through AI capabilities in the obesity therapy area.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Collaborate with the primary market research team to integrate consumer insights using existing data
Explore new Artificial Intelligence (AI) capabilities to enhance deliverables — including insights visualization and knowledge management of market research reports across the obesity therapy area
Partner with analytics team members to develop approaches for capturing and addressing cross-team business questions
Partnering with the team in designing, planning, and execution of workshops
Qualification
Required
Must be a current student enrolled or recently graduated (graduation date no earlier than April 2026) at/from an accredited college or university pursuing at least a bachelor's degree
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
A completed or in progress undergraduate degree in Business Administration, Marketing, Artificial Intelligence or a related discipline preferred
Class year of a junior or senior preferred
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
Labiotech UG
2026-01-24
bloomberglaw.com
2026-01-24
Company data provided by crunchbase